JP2018500353A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500353A5 JP2018500353A5 JP2017533932A JP2017533932A JP2018500353A5 JP 2018500353 A5 JP2018500353 A5 JP 2018500353A5 JP 2017533932 A JP2017533932 A JP 2017533932A JP 2017533932 A JP2017533932 A JP 2017533932A JP 2018500353 A5 JP2018500353 A5 JP 2018500353A5
- Authority
- JP
- Japan
- Prior art keywords
- solid oral
- pharmaceutically acceptable
- water
- compound
- oral preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462096812P | 2014-12-24 | 2014-12-24 | |
| US62/096,812 | 2014-12-24 | ||
| PCT/US2015/000515 WO2016105582A1 (en) | 2014-12-24 | 2015-12-23 | Compositions for ileo-jejunal drug delivery |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018500353A JP2018500353A (ja) | 2018-01-11 |
| JP2018500353A5 true JP2018500353A5 (https=) | 2019-02-07 |
| JP6687248B2 JP6687248B2 (ja) | 2020-04-22 |
Family
ID=55361929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533932A Active JP6687248B2 (ja) | 2014-12-24 | 2015-12-23 | 回腸−空腸薬物送達用組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20180193274A1 (https=) |
| EP (1) | EP3236943B1 (https=) |
| JP (1) | JP6687248B2 (https=) |
| DK (1) | DK3236943T3 (https=) |
| ES (1) | ES2942642T3 (https=) |
| FI (1) | FI3236943T3 (https=) |
| HR (1) | HRP20230305T1 (https=) |
| HU (1) | HUE061809T2 (https=) |
| LT (1) | LT3236943T (https=) |
| MA (1) | MA41265B1 (https=) |
| PL (1) | PL3236943T3 (https=) |
| PT (1) | PT3236943T (https=) |
| RS (1) | RS64139B1 (https=) |
| SI (1) | SI3236943T1 (https=) |
| WO (1) | WO2016105582A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME03455B (me) | 2012-09-10 | 2020-01-20 | Principia Biopharma Inc | Jedinjenja pirazolopirimidina kao inhibitori kinaze |
| HRP20170217T1 (hr) | 2013-04-25 | 2017-04-21 | Beigene, Ltd. | Fuzinirani heterociklički spojevi kao inhibitori protein kinaze |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| PT3107544T (pt) | 2014-02-21 | 2021-01-05 | Principia Biopharma Inc | Sais e forma sólida de um inibidor de btk |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| US10485797B2 (en) | 2014-12-18 | 2019-11-26 | Principia Biopharma Inc. | Treatment of pemphigus |
| TW201718572A (zh) | 2015-06-24 | 2017-06-01 | 普林斯匹亞生物製藥公司 | 酪胺酸激酶抑制劑 |
| AU2017269335B2 (en) | 2016-05-26 | 2021-07-01 | Recurium Ip Holdings, Llc | EGFR inhibitor compounds |
| MA45547A (fr) | 2016-06-29 | 2019-05-08 | Principia Biopharma Inc | Formulations à libération modifiée à base de 2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidine-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétane-3-yl)pipérazine-1-yl]pent-2-ènenitrile |
| US10864203B2 (en) | 2016-07-05 | 2020-12-15 | Beigene, Ltd. | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
| CA3033827A1 (en) * | 2016-08-16 | 2018-02-22 | Beigene, Ltd. | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl )-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide,preparation, and uses thereof |
| PT3500299T (pt) | 2016-08-19 | 2024-02-21 | Beigene Switzerland Gmbh | Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro |
| CN106588937B (zh) * | 2017-01-16 | 2018-09-21 | 东莞市真兴贝特医药技术有限公司 | 咪唑并吡嗪类化合物及其制备方法和应用 |
| EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES |
| TW202515616A (zh) | 2017-06-26 | 2025-04-16 | 英屬開曼群島商百濟神州有限公司 | 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途 |
| WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY |
| WO2019062328A1 (zh) * | 2017-09-28 | 2019-04-04 | 上海海雁医药科技有限公司 | 苯胺取代的1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途 |
| CN111801334B (zh) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 |
| US11576917B2 (en) | 2018-01-20 | 2023-02-14 | Natco Pharma Limited | Pharmaceutical compositions comprising Ibrutinib |
| KR102328682B1 (ko) | 2018-08-27 | 2021-11-18 | 주식회사 대웅제약 | 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물 |
| WO2020057549A1 (en) | 2018-09-18 | 2020-03-26 | Beijing Innocare Pharma Tech Co., Ltd. | Crystalline forms of 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide |
| CA3117009A1 (en) * | 2018-11-06 | 2020-05-14 | Beijing Innocare Pharma Tech Co., Ltd. | Amorphous solid dispersion comprising 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide |
| WO2020102304A1 (en) * | 2018-11-13 | 2020-05-22 | Rain Therapeutics Inc. | Combination of a kinase inhibitor and an electrolyte, compositions and methods comprising the same |
| EP3666262B1 (en) * | 2018-12-10 | 2021-11-10 | Aphaia IP AG | Pharmaceutical oral dosage forms for treatment of metabolic disorders and related diseases through orchestrated release of enterokines |
| CN109851725A (zh) * | 2018-12-29 | 2019-06-07 | 华南理工大学 | 纳米纤维素-聚丙烯酰胺-明胶复合水凝胶、其制备方法及应用 |
| WO2020249001A1 (zh) | 2019-06-10 | 2020-12-17 | 百济神州瑞士有限责任公司 | 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 |
| EP4013749B1 (en) | 2019-08-15 | 2026-03-11 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| TWI877239B (zh) | 2019-10-14 | 2025-03-21 | 美商普林斯匹亞生物製藥公司 | 藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌-1-基]戊-2-烯腈來治療免疫血小板減少症之方法 |
| CN114502144A (zh) * | 2019-10-24 | 2022-05-13 | 韩美药品株式会社 | 包含抑制癌细胞生长的酰胺衍生物的药物制剂以及包含其的药物产品 |
| JP2023511105A (ja) | 2020-01-22 | 2023-03-16 | プリンシピア バイオファーマ インコーポレイテッド | ２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）－１ｈ－ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルの結晶形態 |
| US20240075042A1 (en) * | 2020-11-02 | 2024-03-07 | Black Diamond Therapeutics, Inc. | Method of treating cancers with alkyne substituted quinazoline derivatives |
| MA63498A1 (fr) * | 2021-06-10 | 2024-07-31 | Hikma Pharmaceuticals Usa Inc. | Formes posologiques orales d'ibrutinib |
| CN113855695B (zh) * | 2021-11-01 | 2023-06-06 | 上海理工大学 | 一种结肠释药口服复方药物组合物及其制备方法 |
| CN114181159B (zh) * | 2021-12-28 | 2024-02-20 | 南通大学 | 含2,4,5-三取代嘧啶酰肼衍生物及其制备方法与应用 |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
| CN116473923B (zh) * | 2023-05-29 | 2024-05-14 | 杭州剂泰医药科技有限责任公司 | 一种奈拉替尼固体分散体组合物及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013059738A2 (en) * | 2011-10-19 | 2013-04-25 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
| CN104487441B (zh) * | 2012-06-18 | 2018-06-01 | 普林斯匹亚生物制药公司 | 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶 |
| WO2014004707A1 (en) | 2012-06-29 | 2014-01-03 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
| ME03455B (me) * | 2012-09-10 | 2020-01-20 | Principia Biopharma Inc | Jedinjenja pirazolopirimidina kao inhibitori kinaze |
| CN105101956B (zh) * | 2013-01-05 | 2018-12-07 | 埃尔舍利克斯治疗公司 | 包含双胍的延迟释放组合物 |
-
2015
- 2015-12-23 DK DK15834774.0T patent/DK3236943T3/da active
- 2015-12-23 US US15/539,100 patent/US20180193274A1/en not_active Abandoned
- 2015-12-23 FI FIEP15834774.0T patent/FI3236943T3/fi active
- 2015-12-23 PL PL15834774.0T patent/PL3236943T3/pl unknown
- 2015-12-23 ES ES15834774T patent/ES2942642T3/es active Active
- 2015-12-23 HR HRP20230305TT patent/HRP20230305T1/hr unknown
- 2015-12-23 EP EP15834774.0A patent/EP3236943B1/en active Active
- 2015-12-23 MA MA41265A patent/MA41265B1/fr unknown
- 2015-12-23 LT LTEPPCT/US2015/000515T patent/LT3236943T/lt unknown
- 2015-12-23 RS RS20230281A patent/RS64139B1/sr unknown
- 2015-12-23 PT PT158347740T patent/PT3236943T/pt unknown
- 2015-12-23 JP JP2017533932A patent/JP6687248B2/ja active Active
- 2015-12-23 HU HUE15834774A patent/HUE061809T2/hu unknown
- 2015-12-23 SI SI201531939T patent/SI3236943T1/sl unknown
- 2015-12-23 WO PCT/US2015/000515 patent/WO2016105582A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018500353A5 (https=) | ||
| HRP20230305T1 (hr) | Pripravci za ileo-jejunalnu dostavu lijeka | |
| JP6815358B2 (ja) | 時限パルス放出システム | |
| ES2590479T3 (es) | Sistemas de administración de fármacos que comprenden fármacos débilmente básicos y ácidos orgánicos | |
| JP4488171B2 (ja) | 有効成分ブデソニドのための医薬組成物 | |
| JP6161701B2 (ja) | 徐放特性及びエタノールの影響に対する耐性を有する医薬又は栄養補助組成物 | |
| ES2582453T3 (es) | Forma farmacéutica oral sólida contra el uso indebido y dotada de un perfil específico de liberación modificada | |
| JP5819329B2 (ja) | アルコール耐性腸溶性医薬組成物 | |
| JP2008540419A5 (https=) | ||
| US20040126427A1 (en) | Extended release dosage forms of propranolol hydrochloride | |
| JP2014208655A5 (https=) | ||
| WO2016193034A1 (en) | Pharmaceutical or nutraceutical composition with resistance against the influence of ethanol | |
| JP2014528431A5 (https=) | ||
| US20100247645A1 (en) | Pharmaceutical combination of aliskiren and valsartan | |
| JP2009537611A5 (ja) | リポ酸のペレット | |
| EP3223797A1 (en) | Pharmaceutical or nutraceutical composition with resistance against the influence of ethanol | |
| CN101010070A (zh) | 药物组合物 | |
| RU2018137359A (ru) | Пероральные фармацевтические композиции месалазина | |
| WO2005055955B1 (en) | DOSING METHODS FOR ß-D-2’,3’-DIDEOXY-2’,3’-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY | |
| JP2017534668A5 (https=) | ||
| JP2018521030A5 (https=) | ||
| CN1972674B (zh) | 多层形式的药物 | |
| US20150140089A1 (en) | Novel formulations of nitrofurans including nifurtimox with enhanced activity with lower toxicity | |
| RU2018137323A (ru) | Пероральные фармацевтические композиции никотинамида | |
| JP2007530492A5 (https=) |